Drug firm Alembic Pharmaceuticals on Tuesday said it has received approval from the United States (US) health regulator for Solifenacin Succinate tablets, used for treatment of over-active bladder.
The approved products is therapeutically equivalent to the reference listed drug, Vesicare tablets of Astellas Pharma US Inc.
The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Solifenacin Succinate tablets in the strengths of 5 mg and 10 mg, Alembic Pharmaceuticals said in a BSE filing.
Quoting IQVIA sales data, the company said, Solifenacin Succinate tablets 5 mg and 10 mg had an estimated market size of USD 967 million for 12 months, ending December 2018.
The company said it now has a total of 94 ANDA approvals from the USFDA.
Shares of Alembic Pharmaceuticals were trading at Rs 533.40 apiece, up 0.77 per cent, on the Bombay Stock Exchange (BSE).
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.